Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma. Issue 17 (29th May 2015)

• Record Type: Journal Article
• Authors: Wang, Hui; Liu, Ying; Wang, Xiu; Liu, Donghui; Sun, Zhiqiang; Wang, Chun; Jin, Gang; Zhang, Beiguang; Yu, Shilong
• Is Part Of: Cancer. Volume 121:Issue 17(2015)
• Page Start: 2917
• Page End: 2925
• Publication Date: 2015-05-29
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.29456
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr29456-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>The objective of this study was to determine the efficacy and safety of locoregional therapy (LRT) combined with arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) treatment in primary hepatocellular carcinoma (HCC) patients.</p> </sec> <sec id="cncr29456-sec-0002" sec-type="section"> <title>METHODS</title> <p>One hundred twenty‐five primary HCC patients were recruited for a randomized controlled study. Patients were randomly divided into group A (n = 61) and group B (n = 64). All patients received transarterial chemoembolization. Group A patients were given As<sub>2</sub>O<sub>3</sub> at 10 mg/d for 4 courses (21 days per course) with a 2‐week interval between courses. Survival times, therapeutic responses, extrahepatic metastases, and adverse events were recorded.</p> </sec> <sec id="cncr29456-sec-0003" sec-type="section"> <title>RESULTS</title> <p>A better therapeutic response was found in group A patients, as shown by higher objective response rate (ORR) and clinical benefit rate (CBR) values in group A versus group B (ORR, 81.96% [95% confidence interval (CI), 72.32%‐91.62%] vs 59.37% [95% CI, 47.34%‐71.41%], χ<sup>2</sup> = 7.650, <italic>P</italic> < .05; CBR, 95.08% [95% CI, 89.66%‐100.00%] vs 81.25% [95% CI, 71.69%‐90.81%], χ<sup>2</sup> = 5.659, <italic>P</italic> < .05). There were fewer patients with extrahepatic metastases in group A versus group B (group A, 6 cases or 9.84% [95% CI, 2.36%‐17.31%]; group B, 12 cases or 18.75% [95% CI, 9.19%‐28.31%]). The survival rate for group A patients was significantly higher than that for group B patients (<italic>P</italic> < .05). No significant differences were found between the 2 groups in terms of hematology or digestive system, liver, or kidney dysfunction except for facial and limb edema.</p> </sec> <sec id="cncr29456-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>LRT combined with As<sub>2</sub>O<sub>3</sub> treatment prevents extrahepatic metastasis and prolongs the survival time for primary HCC patients. <bold><italic>Cancer</italic> 2015;121:2917–2925.</bold> © <italic>2015 American Cancer Society</italic>.</p> </sec> </abstract>